Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2
- PMID: 32979386
- PMCID: PMC7587068
- DOI: 10.1016/j.jpeds.2020.09.054
Use of tocilizumab in multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2
Comment in
-
Reply.J Pediatr. 2021 Jan;228:315-316. doi: 10.1016/j.jpeds.2020.09.055. Epub 2020 Nov 2. J Pediatr. 2021. PMID: 32979385 No abstract available.
Comment on
-
Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York City.J Pediatr. 2020 Sep;224:24-29. doi: 10.1016/j.jpeds.2020.06.045. Epub 2020 Jun 14. J Pediatr. 2020. PMID: 32553861 Free PMC article.
References
-
- Dufort E.M., Koumans E.H., Chow E.J., Rosenthal E.M., Muse A., Rowlands J. New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383:347–358. - PMC - PubMed
-
- Nozawa T., Imagawa T., Ito S. Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki's disease. N Engl J Med. 2017;377:1894–1896. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical